Recent insider trends for AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) have caught the attention of investors. Insider activity is often a strong indicator of future performance in a stock, and if the data on ACRX is anything to go by, investors should pay attention.
Institutions own 23.33% of AcelRx Pharmaceuticals, Inc. (ACRX)’s shares. The total value of these holdings, in millions, is $23. Among active positions in the latest quarter, 25 holders increased their positions by a total of 1.7 million shares, 35 holders decreased the positions by a total of 4.75 million shares, and 17 holders held their positions. This works out to a net decrease in ownership of 3.05 million shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 10 holders initiated new positions by a total of 732370 shares and 18 holders exited their positions by a total of 574027 shares. This nets out to an increase of 158343 shares and is a bullish sign for ACRX.
In the last three months, insiders executed a total of 7 trades. 5 of these were buys and 2 were sells. Insider ownership increased by a total of 13012 shares, which suggests that ACRX’s key executives are feeling more optimistic about the outlook for the stock. The data from the past twelve months tells a different story: insiders executed 6 buys and 3 sells, and ownership decreased by a net of 845987 shares.
Short interest is another tool that analysts use to gauge investor sentiment. It represents the number of a stock’s shares that are being shorted by investors. AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)’s short interest is 5.13 million shares, or 19.23% of the float. This represents an increase of 7% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
Ownership trends and trading patterns can be useful tools for predicting a stock’s performance, but it’s also important to consider the technicals in order to form a more comprehensive view. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that ACRX is a sell, which implies that ACRX is expected to underperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bullish. Technical indicators (also) suggest that AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) is overvalued.